pseudobulbar affect


Also found in: Dictionary, Thesaurus, Legal, Acronyms, Encyclopedia, Wikipedia.
Related to pseudobulbar affect: Pseudobulbar palsy

pseudobulbar affect

Abbreviation: PBA
The labile expression of emotions (as by pathological or inappropriate laughing or crying) out of proportion to the feelings experienced by the patient. PBA is characteristic of patients with amyotrophic lateral sclerosis, multiple sclerosis, and other brain diseases.
See also: affect
References in periodicals archive ?
Current concepts in the pharmacotherapy of pseudobulbar affect.
The differential diagnosis of pseudobulbar affect (PBA).
Review of pseudobulbar affect including a novel and potential therapy.
Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect.
Treatments for pseudobulbar affect initially included only antidepressants and levodopa (a medication more commonly used to treat Parkinson's disease), says Dr.
Pseudobulbar affect (PBA)--a secondary effect of MS, ALS, and a variety of other unrelated neurologic conditions--"is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying," according to the FDA-approved prescribing information, which says that these episodes "typically occur out of proportion or in-congruent to the underlying emotional state.
The differential diagnosis of pseudobulbar affect (IEED): Distinguishing IEED among disorders of mood and affect.
Pseudobulbar affect (PBA) symptoms were found in the study to be more common among neurology patients under age 65; however, the adverse impact of PBA symptoms upon quality of life was greater in the elderly, Dr.
M2 EQUITYBITES-April 29, 2013-Avanir Pharmaceuticals Inc gets EMA CHMP's positive opinion for NUEDEXTA for pseudobulbar affect management in the EU(C)2013 M2 COMMUNICATIONS http://www.
M2 PHARMA-April 29, 2013-Avanir Pharmaceuticals Inc gets EMA CHMP's positive opinion for NUEDEXTA for pseudobulbar affect management in the EU(C)2013 M2 COMMUNICATIONS
The authors, in describing the control groups in an earlier phase III study of DMQ for the treatment of patients with pseudobulbar affect (PBA), state, "However, the control conditions may not have been adequate.
Trial, usage, and familiarity of Avanir's Nuedexta, an agent launched for the treatment of pseudobulbar affect in late January 2011, continues to be limited after four months of commercial availability.